Hydroxychloroquine found ‘no better than placebo pills’ in preventing COVID-19 in high risk people, New England Journal of Medicine study finds

Print Friendly, PDF & Email
hydroxychloroquine ap

A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in people in close contact with someone with the disease.

Results published [June 4] by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus. The drug did not seem to cause serious harm, though — about 40% on it had side effects, mostly mild stomach problems.

“We were disappointed. We would have liked for this to work,” said the study leader, Dr. David Boulware, an infectious disease specialist at the University of Minnesota.

Related article:  Why this COVID-19 spike is different: Current U.S. mutated version much more infectious than first wave virus but no more deadly

Boulware’s study involved 821 people in the United States and Canada living with someone diagnosed with COVID-19 or at high risk of getting it because of their job — doctors, nurses, ambulance workers who had significant exposure to a sick patient while not wearing full protective gear.

“There’s basically no effect. It does not prevent infection,” he said of the drug. Even if it were to give some slim advantage, “we’d want a much larger effect” to justify its use and risk of side effects for preventing illness, he said.

Read the original post

Outbreak Featured
Infographics: Key charts illustrate split between vaccinated and unvaccinated America

Infographics: Key charts illustrate split between vaccinated and unvaccinated America

Three in 10 American adults remain unvaccinated, according to the latest survey from the KFF. But they’re not a monolith ...
Are GMOs and pesticides threatening bees?

Are GMOs and pesticides threatening bees?

First introduced in 1995, neonicotinoids ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.